Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

August 30, 2019

Study Completion Date

August 30, 2019

Conditions
Hereditary Hemorrhagic Telangiectasia
Interventions
DRUG

Topical timolol maleate

"* Topical timolol maleate 0.5% drops~* Applied twice daily for 12 weeks (84 days) or until disappearance of lesions~* Study drops will be applied to 3 cutaneous telangiectasias per patient"

DRUG

placebo saline drops

Applied twice daily for 12 weeks (84 days) or until disappearance of lesions to 1 cutaneous telangiectasias per patient.

Trial Locations (1)

M5B 1W8

St. Michael's Hospital, Toronto

All Listed Sponsors
collaborator

University of California, San Francisco

OTHER

collaborator

The Hospital for Sick Children

OTHER

collaborator

University of Toronto

OTHER

collaborator

Sunnybrook Health Sciences Centre

OTHER

collaborator

Toronto Metropolitan University

OTHER

collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

lead

Unity Health Toronto

OTHER

NCT01752049 - Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept | Biotech Hunter | Biotech Hunter